Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field.

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE Current Atherosclerosis Reports Pub Date : 2025-01-09 DOI:10.1007/s11883-024-01271-x

Francesco Di Giacomo-Barbagallo, Natalia Andreychuk, Roberto Scicali, Ana Gonzalez-Lleó, Salvatore Piro, Lluis Masana, Daiana Ibarretxe

{"title":"Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field.","authors":"Francesco Di Giacomo-Barbagallo, Natalia Andreychuk, Roberto Scicali, Ana Gonzalez-Lleó, Salvatore Piro, Lluis Masana, Daiana Ibarretxe","doi":"10.1007/s11883-024-01271-x","DOIUrl":null,"url":null,"abstract":"Purpose of the review: A significant number of patients fail to achieve target LDL cholesterol (LDL-C) levels. This review aims to explore why inclisiran, a novel class of LLT, should be considered a valuable addition to the current treatment options.Recent findings: Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 synthesis specifically in the hepatocytes. The drug remains in circulation for less than 48 h, but its effect lasts for over six months. Two subcutaneous injections per year consistently lowers LDL-C by approximately 55% with a favorable safety profile. In combination with other LLTs, it can achieve LDL-C reductions of over 80%, supporting its role in high-intensity LLT strategies. Inclisiran represents a novel class of LLT. Administered biannually, reduces baseline LDL-C levels by half. Additionally, it has a strong safety profile. Due to its pharmacokinetic properties, is likely to improve adherence to LLT and persistently maintain low LDL-C levels.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"25"},"PeriodicalIF":5.7000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717820/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-024-01271-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of the review: A significant number of patients fail to achieve target LDL cholesterol (LDL-C) levels. This review aims to explore why inclisiran, a novel class of LLT, should be considered a valuable addition to the current treatment options.

Recent findings: Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 synthesis specifically in the hepatocytes. The drug remains in circulation for less than 48 h, but its effect lasts for over six months. Two subcutaneous injections per year consistently lowers LDL-C by approximately 55% with a favorable safety profile. In combination with other LLTs, it can achieve LDL-C reductions of over 80%, supporting its role in high-intensity LLT strategies. Inclisiran represents a novel class of LLT. Administered biannually, reduces baseline LDL-C levels by half. Additionally, it has a strong safety profile. Due to its pharmacokinetic properties, is likely to improve adherence to LLT and persistently maintain low LDL-C levels.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Inclisiran，在拥挤的治疗领域出现一种新药物的原因。

综述的目的：大量患者未能达到目标LDL- c水平。这篇综述旨在探讨为什么inclisiran，一种新型的LLT，应该被认为是当前治疗方案的一个有价值的补充。最近发现：Inclisiran是一种小干扰RNA (siRNA)，特异性靶向肝细胞中PCSK9的合成。该药的循环时间不到48小时，但其效果持续6个月以上。每年两次皮下注射持续降低LDL-C约55%，具有良好的安全性。与其他LLT结合，它可以实现LDL-C降低80%以上，支持其在高强度LLT策略中的作用。Inclisiran是一种新型的LLT。每半年服用一次，可使基线LDL-C水平降低一半。此外，它还具有很强的安全性。由于其药代动力学特性，可能会改善对LLT的依从性并持续维持低LDL-C水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.